City of Hope Medical Center: Lymphoma, T-Cell, Cutaneous trials

The registry lists 11 Lymphoma, T-Cell, Cutaneous studies with City of Hope Medical Center as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 6Phase 2 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell LymphomaRecruitingNCT04930653Phase 2
• Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29RecruitingNCT04670874
• Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
• Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedNCT02342782Phase 1
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
• Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaCompletedNCT00641381Phase 1